ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 23 October 2026 APPENDIX 4C: QUARTER ENDED 30 SEPTEMBER 2026 Highlights for the quarter: • Reached clinical readiness, with the first two batches successfully manufactured and released for patient use during September 2026. •...